Avipendekin pegol

N/A

Report date: 2025/02/14 20:00:40

Base Information

Drug NameAvipendekin pegol
Drug Alias NamePolymer-conjugated IL-15NKTR-255
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-15 receptor subunit alpha stimulants
TargetsInterleukin-15 receptor subunit alpha
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsColorectal Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesNektar TherapeuticsThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsColorectal NeoplasmsMultiple Myeloma +[5] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A